News Novartis AG

Equities

NOVN

CH0012005267

Market Closed - Swiss Exchange Other stock markets 11:30:41 2023-12-08 am EST			5-day change	1st Jan Change
84.72 ^CHF	+0.56%		-0.77%	+1.35%

Dec. 08	Novartis welcomes "significant milestone" for Kisqali	AN
Dec. 08	Novartis Says Latest Kisqali Trial Analysis Reinforces Over 25% Reduction in Risk of Breast Cancer Recurrence	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Novartis welcomes "significant milestone" for Kisqali	Dec. 08	AN
Novartis Says Latest Kisqali Trial Analysis Reinforces Over 25% Reduction in Risk of Breast Cancer Recurrence	Dec. 08	MT
Novartis: positive results in early breast cancer	Dec. 08	CF
Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissions	Dec. 08	GL
Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer	Dec. 08	CI
New entries in MarketScreener's Europe portfolio	Dec. 08
Daiichi Sankyo Subsidiary, Plexxikon, Wins Patent Lawsuit; Novartis to Pay $182 Million Settlement	Dec. 07	MT
European Midday Briefing : Disappointing Data Weigh on Sentiment	Dec. 07	DJ
Swiss Market Index Extends Gains as Dovish Narrative Lifts Sentiment	Dec. 06	MT
Merck Shares Slump After Multiple Sclerosis Drug Fails in Late-Stage Trials	Dec. 06	DJ
Novartis Says FDA Approved Oral Monotherapy for Blood Disorder	Dec. 06	MT
Novartis: FDA approval in HPN	Dec. 06	CF
Novartis Receives FDA Approval for Fabhalta Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH	Dec. 06	CI
Novartis Wins First-in-Class US FDA Nod for Rare Blood Disorder Drug	Dec. 05	MT
Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNH	Dec. 05	GL
Merck KGaA suffers major blow as MS drug fails in late-stage trials	Dec. 05	RE
Merck KGaA says MS drug fails in late-stage trials	Dec. 05	RE
Anything is possible	Dec. 05
Key Jobs Report Awaited as Exchange-Traded Funds, Equity Futures Decline Pre-Bell Tuesday	Dec. 05	MT
NOVARTIS AG : JP Morgan remains Neutral	Dec. 05	ZD